A patient has died after receiving the high dose of Neurogene’s Rett syndrome gene therapy candidate.

Philips unveiled the next generation of its MRI scanner, with sealed magnets that do not need to be recharged with liquid helium coolant.

VC firm Versant Ventures is unveiling Pep2Tango Therapeutics, a biotech developing next-gen obesity therapeutics with multiple targets in hopes of overcoming limitations tied to GLP-1 treatments.

After collecting an FDA greenlight earlier this year, BD is launching a real-world study to see if its self-collection kits for HPV testing will improve cervical cancer screening rates among underserved communities in southern Texas.

Earlier this year, Intuitive Surgical warned that supplies may be tight in the months ahead as it continues to roll out the latest iteration of its da Vinci robot. And, while the company has made some gains—installing some 110 da Vinci 5 systems in the third quarter of this year, versus 70 in the quarter prior—Intuitive held to its previous timeline, saying it plans to have production scaled up and running up for a broader launch in mid-2025.

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients.

Three months after revealing that its respiratory syncytial virus (RSV) preventive antibody clesrovimab had passed muster in a phase 2b/3 trial, Merck is putting numbers to the claim.

With its lead candidate in a phase 3 trial for a rare eye cancer, Aura Biosciences is looking to expand the drug into a more common disease: bladder cancer.

Just as Smita Gopinath, Ph.D., was setting up her microbiology and immunology lab at Harvard T.H. Chan School of Public Health, the COVID-19 pandemic struck and shut things down. With no lab space or animal facility to house mice she could work with, Gopinath adapted to do whatever research she could.

Noema Pharma has racked up a phase 2a win for its Tourette syndrome drug candidate, reporting hits on the primary and key secondary endpoints in a small study of the former Roche molecule.